Otras herramientas para el tratamiento del dolor en Urgencias

  1. AEMPS-CIMA. Ficha técnica de Velyntra®. Disponible en: https://cima.aemps.es/cima/dochtml/ft/89051/FT_89051.htmh
  2. Manhães M, Cesar M, Justo R, Geller M, Suchmacher M, Cisne R. The role of nucleotides in glial cells during peripheral nerve trauma and compressive disorders. In: Maurício AC, editor. Peripheral nerve regeneration: from surgery to new therapeutic approaches including biomaterials and cell based therapies development. Rijeka: InTech; 2017. doi:10.5772/68068.
  3. Fugleholm K, Hermandez Bonilla J, Hurtado N. The surgery of peripheral nerves (including tumors). In: Handbook of Clinical Neurology. Vol 115. Amsterdam: Elsevier; 2013. p. 781-802.
  4. Hermandez Bonilla J, Hurtado N. Simulación 3D de la reconstrucción de tejidos nerviosos en ambiente natural y controlado, usando autómatas celulares. 2016. doi:10.13140/RG.2.2.20651.34087.
  5. The Foundation for Peripheral Neuropathy [Internet]. National Health Service (UK); Mayo Clinic; 2025. Disponible en: https://www.foundationforpn.org/
  6. Mayo Clinic [Internet]. National Health Service (UK); 2025. Disponible en: http://mayoclinic.org/
  7. López Rodríguez R, Pérez González M, Calderón Pascual V (Coords.). Use conditions for certain substances other than vitamins, minerals and plants in food supplements. Rev Comité Científico AESAN. 2012;17:11-234. Disponible en: https://www.aesan.gob.es/AECOSAN/docs/documentos/publicaciones/revistas_comite_cientifico/comite_cientifico_17.pdf
  8. Calderon-Ospina CA, Nava-Mesa MO. B vitamins in the nervous system: current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin. CNS Neurosci Ther. 2020;26(1):5-13. doi:10.1111/cns.13207.
  9. Geller M, Oliveira L, Nigri R, Mezitis SG, Ribeiro MG, et al. B vitamins for neuropathy and neuropathic pain. Vitam Miner. 2017;6:161. doi:10.4172/2376-1318.1000161.
  10. Durany N. Biochemistry of cytosine and uracil nucleotides and their neurophysiological significance. Oral presentation at: Beijing Symposium; 2010 Jan 22; Beijing, China.
  11. Gella A, Martiañez T, Lamarca A, Gutierrez C, Durany N, et al. A nucleotide-based drug protects against glutamate- and MPP+-induced neurotoxicity. Neurosci Med. 2011;2(2):154-60. doi:10.4236/nm.2011.22022.
  12. Martiáñez T, Gella A, Lamarca A, Durany N, et al. UTP affects the Schwannoma cell line proteome through P2Y receptors leading to cytoskeletal reorganization. Proteomics. 2012;12(1):145-56. DOI:10.1002/pmic.201100187.
  13. Martiáñez T, Gella A, Lamarca A, Durany N, et al. N-cadherin expression is regulated by UTP in schwannoma cells. Purinergic Signal. 2013;9(2):259-70. DOI:10.1007/s11302-012-9348-x.
  14. Wattig B, Schalow G, Heydenreich F, Warzok R, Cervós-Navarro J. Enhancement of nerve fibre regeneration by nucleotides after peripheral nerve crush damage: electrophysiologic and morphometric investigations. Arzneimittelforschung. 1992;42(9):1075-8.
  15. Okada M, Nakagawa T, Minami M, Satoh M. Analgesic effects of intrathecal administration of P2Y nucleotide receptor agonists UTP and UDP in normal and neuropathic pain model rats. J Pharmacol Exp Ther. 2002;303(1):66-73. DOI: 10.1124/jpet.102.036079.
  16. Danilov AB, Kurushina OV, Prokopenko SV, Karakulova YV, Shcherbanosova TA, Kurganova YM, et al. Preliminary results of a multicenter observational study of Keltican® complex in patients with radiculopathy and chronic lumbar pain in Russia. Manage Pain. 2020;1:36-40.
  17. Povedano M, Martínez Y, Tejado A, Arroyo P, Tebe C, Lorenzo JL, et al. Observational pilot study of patients with carpal tunnel syndrome treated with Nucleo CMP Forte™. Pain Manag. 2019;9(2):123-9.DOI: 10.2217/pmt-2018-0050.
  18. Goldberg H, Mibielli MA, Nunes CP, Goldberg SW, Buchman L, Mezitis SG, et al. A double-blind, randomized, comparative study of the use of a combination of uridine triphosphate trisodium, cytidine monophosphate disodium, and hydroxocobalamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgias. J Pain Res. 2017;10:397-404. DOI: 10.2147/JPR.S123045.
  19. Mibielli MA, Nunes CP, Scussel AB, Neto MS, Oliveira L, Geller M. Symptomatic improvement in acute, non-traumatic spine pain with uridine triphosphate, cytidine monophosphate, and hydroxocobalamin. PST. 2014;2(1). DOI: 10.4236/pst.2014.21002.
  20. Mibielli MA, Nunes CP, Cohen JC, Scussel AB Jr, Higashi R, Bendavit GG, et al. Treatment of acute, non-traumatic pain using diclofenac-cholestyramine, uridine triphosphate, cytidine monophosphate, and hydroxycobalamin. Proc West Pharmacol Soc. 2010;53:5-12.
  21. Goldberg H, Scussel Jr AR, Cohen JC, Rzetelna H. Neural compression-induced neuralgias: clinical evaluation of nucleotides associated with vitamin B12. Rev Bras Med. 2009;66(11):380-5.
  22. Lärm G, Rückert U, Hedding-Eckerich M. Neurotropic nutrients promote recovery after intervertebral disc operations. Extracta Orthop. 2008;2:44-5.
  23. Dzjak LA, Mizyakina EV, Khaitov PA. Administration experience of Nucleo CMP Forte in vertebral degenerative-dystrophic pathologies. Ukr Med. 2007;112:11-4.
  24. Lauretti GR, Omais M, Pereira AC, de Mattos AL. Clinical evaluation of the cytidine-uridine-hydroxicobalamine complex as adjuvant in chronic neuropathic low back pain. Coluna/Columna. 2005;3(2):73-6. 
  25. Liebau C, Koch H, Merk HR. Accelerated pain reduction after uridin-5’-monophosphate in acute lumbago. Orthop Praxis. 2003;39(5):320-4.
  26. Hörterer H. Efficient treatment of peripheral neuropathy in lumbago: rapid symptom improvement through neuronal regeneration. Extr Orthop. 2001;9:1-3.
  27. De Mora E, Monfort R. Estudio multicéntrico de una asociación de nucleótidos en el tratamiento del dolor neuromuscular. Phronesis. 1991;12(1):1-5.
  28. Klein KG. Assessment of nucleotides and vitamin B12 versus B vitamin combinations in lumbar radicular irritation syndrome. Biometrischer Bericht. ANFOMED; 1990.
  29. Michael J. Treatment of vertebral and radicular syndromes after disc herniation surgery. Extracta Orthop. 1988;11(5):277-82.
  30. Nunes C, Scussel Jr AB, Goldberg H, Goldwasser G, Oliveira L, Rzetelna H, et al. Alcoholic polyneuropathy: clinical assessment of outcomes following nucleotides and vitamin B12 therapy. Res Neurol Int J. 2013;1:1-16. DOI:10.5171/2013.208067.
  31. Kretschmar C, Kaumeier S, Haase W. Die medikamentöse Therapie der alkoholischen Polyneuropathie. Randomisierte Doppelblindstudie zum Vergleich zweier Vitamin-B-Präparate und eines Nukleotid-Präparates [Medicamentous therapy of alcoholic polyneuropathy. Randomized double-blind study comparing 2 vitamin B preparations and a nucleotide preparation]. Fortschr Med. 1996;114(32):439-43.
  32. Martynyuk L, Makarchuk N, Shved M, Mykhailiv L. Clinical efficacy of Nucleo CMP forte in diabetic peripheral neuropathy. Endocr Abstr. 2017;49:EP420. doi:10.1530/endoabs.49.EP420.
  33. Bouna Seck L, Basse A, Cissé EH, Diedhiou D, Touré K, Ndiaye M, et al. Efficacy and tolerance of cytidine-5’-monophosphate and uridine-5’-triphosphate trisodium in diabetic neuropathy. Int J Med Med Sci. 2015;5(8):284-7.
  34. Pankiv VI. Clinical experience of Nucleo CMP Forte in diabetic polyneuropathy. Int J Endocrinol. 2008;6(18):23-5.
  35. Müller D. Therapie des neuropathischen Schmerzsyndroms: offene Studie zur Wirksamkeit eines Pyrimidinnukleotid-Präparats. Fortschr Med Orig. 2002;120(4):131-3.
  36. Krämer G. Open study to determine the effectiveness and tolerance of Keltican IV in diabetic polyneuropathy. Study N.1.3.902.91. 1991.
  37. Gallai V, Mazzotta G, Montesi S, Sarchielli P, Del Gatto F. Effects of uridine in the treatment of diabetic neuropathy: an electrophysiological study. Acta Neurol Scand. 1992;86(1):3-7. DOI: 10.1111/j.1600-0404.1992.tb08045.x.
  38. Al-Attar Z, Hashim I, Nashtar S. The role of Nucleo-CMP as adjuvant in facial palsy. Int J Med Res Health Sci. 2018;7(3):161-7.
  39. Castellon BW. Blinded, randomized, placebo-controlled study of cytidine monophosphate (Nucleo CMP) in facial paralysis afrigore. Clin Hosp Physiother Serv La Paz. 2001:59.
  40. Sturm E. Facial neuralgias: therapeutic study with nucleotide-vitamin B12 combination. Neurol Psychiatr. 1988;39:1-5.
  41. Cartier L, Castillo JL, Verdugo R. Efecto del núcleo cmp forte en 46 pacientes con paraparesia espástica progresiva. Estudio randomizado y ciego [Effect of the Nucleus CMP forte in 46 patients with progressive spastic paraparesis. Randomized and blind study]. Rev Med Chil. 1996;124(5):583-7.
  42. Hedding-Eckerich M. Treatment of peripheral nerve damage with pyrimidine nucleotides: retrospective analysis of >2000 cases. Der Allgemeinarzt. 2001;16:2-7.
  43. Laurinec K. Regeneration of peripheral nervous system in polyneuropathies. Therapiewoche. 1987;37:1-11.
  44. Castilla-Garrido JM. Acción del N-CMP en enfermedades del sistema nervioso periférico. Panminerva Med. 1973;15(6):305-10.